Panobinostat in Combination With Rituximab For Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 13 May 2017
At a glance
- Drugs Panobinostat (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 14 Jul 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Aug 2015, as reported by ClinicalTrials.gov.
- 06 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 06 Jun 2011 Actual initiation date (Jun 2011) and lead trial investigators added as reported by ClinicalTrials.gov.